Statements (12)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alternativeName |
gptkb:tirzepatide
|
| gptkbp:ATCCode |
none
|
| gptkbp:clinicalTrialPhase |
Phase 2 (as of 2020)
|
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
|
| https://www.w3.org/2000/01/rdf-schema#label |
LY3298176
|
| gptkbp:intendedUse |
treatment of type 2 diabetes
|
| gptkbp:mechanismOfAction |
dual agonist of GLP-1 and GIP receptors
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:status |
investigational
|
| gptkbp:bfsParent |
gptkb:tirzepatide
|
| gptkbp:bfsLayer |
7
|